Ensuring appropriate pre-pregnancy through postnatal care is critical for optimal health of mother and child.
Derek van Amerongen, MD, MS: Let’s change topics slightly and talk about something that’s gotten increasingly important in the last few years: health disparities related to morbidity and mortality and maternal health areas. In many parts of the country, the maternal mortality rate is significantly higher than in places in Central America. The United States overall has a higher maternal mortality rate than any other industrialized country. How do racial disparities tie into this? Let’s start with you, Dr Hawkins.
Soyini Hawkins, MD, MPH, FACOG: There are disparities across the board when it comes to maternal wellness and care. Some of those disparities come from the things we’ve already mentioned, like disparities in access to care. Are they getting to their visits earlier in their pregnancy? In doing so, are they getting the basic preventive treatments that are reflective of their outcomes for childbearing and their actual time in pregnancy? That’s going to be extremely important [in determining] what their results are, how they carry themselves to term, and whether they’re going to be screened for things like cervical shortening. If they’re not coming in early, we can’t know if they need additional treatments and management. Some of the disparities are in the front end, but there are disparities all the way through, unfortunately. With the way we’re monitoring their labs, it can be as simple as that. With the way they present to the hospital if they have pain, elevated blood pressure, or swelling, how is that interpreted across the board? Is it evenly interpreted no matter what their race or culture is? Because all of those are going to affect outcomes when it comes to maternal health.
Of course, the biggest discussion we’ve had in recent years is unconscious bias. Is there a place for us to make improvements in the way we’re partnering with our patients? If they have a birth plan, what does that look like? How can we help them execute in the way that is safe and feels comfortable for them? As providers, we need to be safe in the way that we’re caring for them beyond a birth plan when they get there. They might say something as simple as, “I have chest pain.” [We need to make sure that’s] not brushed off or excused as melodramatic in patient populations that have been sidelined during their disease or symptomatic states? That translates into outcomes. The disparities are extremely important at the front end of how women are being treated when they’re trying to get pregnant. From their planning stages, to getting them to their obstetricians early in their pregnancies, to making sure they receive the best baseline care all the way to the day of delivery.
Transcript edited for clarity.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More
2 Commerce Drive
Cranbury, NJ 08512